Corbus Pharmaceuticals Holdings Inc. (CRBP)
NASDAQ: CRBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CRBP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $42.45M
- EPS (TTM)
- -$6.04
- Dividend yield
- None
- 52-week range
- 2.01 – 12.88
- Day range
- 2.01 – 2.45
- Volume / Avg
- 1.38M / 1.11M
- Beta
- —
- Shares outstanding
- 20.61M
52-week range
CRBP stock today
Shares of Corbus Pharmaceuticals (CRBP) finished lower on Nov 20 at $2.06, a drop of 15.40% or $0.375 per share, versus the S&P 500's 3.70% decline. Shares are 84.0% below their 52-week high of $12.88, set on May 22, 2026 and 2.5% above the 52-week low of $2.01, near the bottom of the past year's range. CRBP is down 74.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 82.8%.
Corbus Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$6.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Corbus Pharmaceuticals
Company profileCorbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Yuval Cohen Ph.D.
- Headquarters
- Norwood, MA
- Employees
- 36
- Website
- corbuspharma.com
Financial highlights
Full financialsCorbus Pharmaceuticals reported a net loss of $78.5 million, compared with a loss of $40.2 million a year earlier. Diluted earnings per share came in at -$5.90.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $881.71K |
| Growth | — | — | — | -100.00% | -77.61% |
| Net income | $-78.54M | $-40.21M | $-44.60M | $-42.35M | $-45.64M |
| EPS (diluted) | $-5.90 | $-3.68 | $-10.31 | $-10.15 | $-11.15 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$34.03+1551.94%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-1.81 vs $-1.45
- Surprise
- -24.83%
CRBP news
All CRBP news- CSPC Receives $15 Mln Milestone Payment From Corbus For CRB-701 LicenseNasdaqCRBP, ET
- Corbus Pharmaceuticals Holdings, Inc. Announces Phase 1b CANYON-1 Trial Data for Obesity Treatment CRB-913Nasdaq
- Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026GlobeNewswire
- Thursday Sector Laggards: Agriculture & Farm Products, Biotechnology StocksNasdaqAGRO, VFF, FATE, CRBP
- Corbus Q3 Loss Widens On Higher R&D Costs; CRB-701 Data Due In Q1 2027NasdaqCRBP, BF.A
- Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate UpdateGlobeNewswire
- Is CRBP a Good Cannabis Investment After Positive Obesity Study Data?NasdaqCRBP, SNY, NVO, LLY
Corbus Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INCRIntercure Ltd. | 3.24 | -7.69% | $42.03M | vs CRBP |
| OSTXOS Therapies Incorporated | 0.803 | -2.12% | $42.00M | vs CRBP |
| BMEABiomea Fusion Inc. | 0.5744 | -2.38% | $41.75M | vs CRBP |
| SPROSpero Therapeutics Inc. | 0.742 | -10.20% | $43.23M | vs CRBP |
| RLYBRallybio Corporation | 15.47 | -0.32% | $43.32M | vs CRBP |
| MREOMereo BioPharma Group plc ADR | 0.26 | -5.45% | $41.52M | vs CRBP |
| ELTXElicio Therapeutics Inc. | 1.45 | -3.33% | $41.05M | vs CRBP |
| TLPHTalphera Inc. | 0.7852 | +6.25% | $40.80M | vs CRBP |
Indexes, lists and sector
Corbus Pharmaceuticals stock FAQ
What is Corbus Pharmaceuticals's stock price today?
CRBP last traded at $2.06 as of Nov 20, 4:00 PM EST, down 15.40% on the day. Prices are delayed at least 15 minutes.
Does Corbus Pharmaceuticals pay a dividend?
No. Corbus Pharmaceuticals does not currently pay a regular cash dividend.
Who is Corbus Pharmaceuticals's CEO?
Dr. Yuval Cohen Ph.D. is the chief executive officer of Corbus Pharmaceuticals Holdings Inc., which has about 36 employees.
Has CRBP ever split its stock?
Yes. The most recent CRBP stock split was a 1-for-30 split on Feb 14, 2023.
What is the CRBP 52-week high?
The 52-week high for CRBP is $12.88 and the 52-week low is $2.01. The stock is currently 84.0% below its high.